March 12, 2025
Novartis has led a wide-ranging litigation campaign to block generic versions of its bestselling cardiovascular drug Entresto that has involved multidistrict litigation, trips to several circuit courts and cases against the federal government. Here, Law360 breaks down how the various cases intersect and what's still playing out.
July 07, 2023
A West Virginia federal judge said Mylan's proposed generic version of heart medication Entresto would infringe a pair of patents that Swiss pharmaceutical giant Novartis has on the brand-name product.